AstraZeneca readies for CJEU ruling in generics case
Managing IP provides a guide to the Court of Justice’s ruling in a case between AstraZeneca and generic-manufacturers about what constitutes abuse of a dominant position in the pharmaceutical sector
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: